Are human CETP mutations and CETP-inhibiting drugs a good or a bad deal?

PubWeight™: 0.75‹?›

🔗 View Article (PMID 16855847)

Published in J Mol Med (Berl) on July 20, 2006

Authors

Friedrich C Luft1

Author Affiliations

1: Franz Volhard Clinic, HELIOS Kliniken Berlin, Medical Faculty of the Charité, Humboldt University, Wiltbergstrasse 50, 13125 Berlin-Buch, Germany. luft@fvk-berlin.de

Articles by these authors

Genetic mutation screening for the low-density lipoprotein receptor. J Mol Med (Berl) (2006) 0.75

Sudden cardiac death is a very serious matter. J Mol Med (Berl) (2004) 0.75

Pancaspase and cardiac function after infarction. J Mol Med (Berl) (2005) 0.75

More reactive and less reactive C-reactive protein. J Mol Med (Berl) (2005) 0.75

A very phoxy business. J Mol Med (Berl) (2003) 0.75

Doxorubicin toxicity in the Iron Age. J Mol Med (Berl) (2006) 0.75

Somatic DNA oxidative damage and coronary disease. J Mol Med (Berl) (2005) 0.75

Is imprinting in printing or in press? J Mol Med (Berl) (2005) 0.75

Suicidal erythrocyte death occurs in the hemolytic uremic syndrome. J Mol Med (Berl) (2006) 0.75

Cardiac reconstruction in the Jurassic Period. J Mol Med (Berl) (2004) 0.75

Oscar M. Helmer, you had it right. J Mol Med (Berl) (2005) 0.75

Phosphate's fate made easier. J Mol Med (Berl) (2005) 0.75